Neumora Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

NMRA$0.50+3.3%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Financial Statements (Unaudited)Condensed Consolidated Balance Sheets

Condensed Cons olidated Balance Sheets

(in thousands)

	March 31,2025	December 31,2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$126,860	$142,148
Restricted cash	1,213	1,213
Short-term marketable securities	122,493	165,430
Prepaid expenses and other current assets	4,300	5,264
Total current assets	254,866	314,055
Property and equipment, net	982	1,140
Operating lease right-of-use assets	900	1,777
Total assets	$256,748	$316,972
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$1,052	$3,307
Accrued liabilities	26,272	24,593
Early exercise liability, current portion	122	133
Operating lease liabilities, current portion	938	1,853
Total current liabilities	28,384	29,886
Early exercise liability, net of current portion	—	22
Total liabilities	28,384	29,908
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock	16	16
Additional paid-in capital	1,243,564	1,234,207
Accumulated other comprehensive gain (loss)	(3)	62
Accumulated deficit	(1,015,213)	(947,221)
Total stockholders’ equity	228,364	287,064
Total liabilities and stockholders’ equity	$256,748	$316,972

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.